193 results
424B5
BPTH
Bio-Path Holdings Inc
19 Apr 24
Prospectus supplement for primary offering
3:28pm
common stock could materially adversely affect our access to the capital markets and any limitation on liquidity or reduction in the price of our common
8-K
EX-10.1
BPTH
Bio-Path Holdings Inc
19 Apr 24
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the- Market Under Nasdaq Rules
9:21am
statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management’s general … and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification, except as would not, individually
424B5
BPTH
Bio-Path Holdings Inc
19 Apr 24
Prospectus supplement for primary offering
9:17am
and the levels of liquidity available to our stockholders. In addition, the delisting of our common stock could materially adversely affect our access
8-K
EX-10.1
BPTH
Bio-Path Holdings Inc
4 Apr 24
Entry into a Material Definitive Agreement
4:35pm
and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management’s general or specific authorization, and (iv … and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification, except as would not, individually
424B5
cxz ns11w4uphbo
4 Apr 24
Prospectus supplement for primary offering
4:33pm
424B5
0vs6wg94stbo9keq
27 Mar 24
Prospectus supplement for primary offering
8:15am
8-K
EX-10.1
qvchfo
26 Mar 24
Entry into a Material Definitive Agreement
8:03am
8-K
EX-99.1
l24dwe
8 Mar 24
Bio-path Holdings Reports Full Year 2023 Financial Results
7:10am
8-K
EX-99.1
1m8j5 tf488thm1pg4k4
10 Jan 24
Targeting Bcl-2 Protein Offers Potential Treatment for Patients Who Have Failed or Relapsed from Venetoclax-Based Frontline Therapy
4:10pm